Tony Hagen

COVID-19 has affected the pace of clinical trials, and the FDA’s most recent notice has been that there will be no “near-term” affect on approvals, said Leslie Fish, RPh, PharmD, who co-presented with Jeffrey Casberg, MS, RPh, in Tuesday’s session, "Drug Pipeline: Traditional Pharmaceuticals and Bisoimilars," at AMCP eLearning Days, which replaced the annual meeting of the Academy of Managed Care Pharmacy.

Private and public institutions are trying to secure supplies of drugs and pharmaceuticals amid travel restrictions and border controls imposed by coronavirus disease 2019 (COVID-19).

China’s biosimilar development engine is supercharged and running on octane, a recent report said.

Clinical trials for biosimilars and other agents are likely to slow down, if not stall, as coronavirus disease 2019 (COVID-19) wends its course, according to a UT Health expert.

The past few years have seen a number of measures implemented that put the brakes on the rapid consolidation of practices and the upward spiral in costs of cancer care borne by CMS.

Panelists discussing quality metrics in oncology were not sure payment and federal policies could keep pace with what's happening on the front lines.

CMS has attempted to tailor ACOs to meet a variety of needs and levels of risk, depending on where parties are in their knowledge level of payment reform.

The timely panel took place just after FDA issued a report on why it feels regulatory oversight of testing is necessary.

When 5% of Medicaid recipients account for 54% of spending, cost is just the beginning of the problem.

CMS' decision to pay primary care physicians to coordinate for seniors with multiple chronic conditions cannot soon enough, if a study in Clinical Diabetes is any sign.